Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study)

Sonja Aho, Emerik Osterlund, Ari Ristimäki, Lasse Nieminen, Jari Sundström, Markus J. Mäkinen, Teijo Kuopio, Soili Kytölä, Annika Ålgars, Raija Ristamäki, Eetu Heervä, Raija Kallio, Päivi Halonen, Leena Maija Soveri, Arno Nordin, Aki Uutela, Tapio Salminen, Hanna Stedt, Annamarja Lamminmäki, Timo MuhonenJuha Kononen, Bengt Glimelius, Helena Isoniemi, Juho T. Lehto, Kaisa Lehtomäki, Pia Osterlund

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Sammanfattning

The primary tumor location (PTL) is associated with the phenotype, metastatic sites, mutations, and outcomes of metastatic colorectal cancer (mCRC) patients, but this has mostly been studied according to sidedness (right vs. left sided). We studied right colon vs. left colon vs. rectal PTL in a real-life study population (n = 1080). Health-related quality of life (HRQoL) was assessed multi-cross-sectionally with QLQ-C30, QLQ-CR29, EQ-5D, and 15D. A chi-square, Kaplan–Meier, and Cox regression were used to compare the groups. The PTL was in the right colon in 310 patients (29%), the left colon in 396 patients (37%), and the rectum in 375 patients (35%). The PTL was associated with distinct differences in metastatic sites during the disease trajectory. The resectability, conversion, and resection rates were lowest in the right colon, followed by the rectum, and were highest in the left colon. Overall survival was shortest for right colon compared with left colon or rectal PTL (median 21 vs. 35 vs. 36 months), with the same trends after metastasectomy or systemic therapy only. PTL also remained statistically significant in a multivariable model. The distribution of symptoms varied according to PTL, especially between the right colon (with general symptoms of metastases) and rectal PTL (with sexual- and bowel-related symptoms). mCRC, according to PTL, behaves differently regarding metastatic sites, resectability of the metastases, outcomes of treatment, and HRQoL.

Originalspråkengelska
Artikelnummer1052
TidskriftCancers
Volym16
Nummer5
ISSN2072-6694
DOI
StatusPublicerad - mars 2024
MoE-publikationstypA1 Tidskriftsartikel-refererad

Bibliografisk information

Publisher Copyright:
© 2024 by the authors.

Vetenskapsgrenar

  • 3122 Cancersjukdomar

Citera det här